Age-Related Macular Degeneration, Allergies, Alopecia Areata, Alpha-Gal Syndrome, ALS, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Cirrhosis, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, DMD, Dravet Syndrome, Fibromyalgia, Graves Disease, Heart Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Kidney Diseases, Leukemia, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Parkinson Disease, Pemphigus Vulgaris, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Thyroid Diseases, Ulcerative Colitis, Vasculitis, Vitiligo
Conditions
Brief summary
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
Interventions
DIAGNOSTIC_TESTSpecimen sample
The study may require a tissue collection and/or a participant survey for participation. Most tissue collected will come from a blood draw; up to 100mL for the health condition group, 60mL for the exceptive condition group, and up to 180mL for the control group (if determined safe for the participant). Participant surveys may involve participant reported outcomes (PROs) or custom participant surveys.
Sponsors
Sanguine Biosciences
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* Persons 18 to 85 years of age at the date of informed consent. * If presenting with a history of a specific condition, the diagnosis is confirmable in the medical record or may be confirmed using other forms of verification including self-reporting. * Understands the procedures and requirements of the study by providing written informed consent (or verbal assent if a legally authorized representative will sign the ICF), including consent for authorization for protected health information disclosure.
Exclusion criteria
* Persons younger than 18 years of age or older than 85 years of age at the date of informed consent. * Receipt of blood products 30 days before the study blood draw. * Receipt of an investigational (unapproved) drug 30 days before the study blood draw. * A confirmable diagnosis of any medical condition that would increase potential phlebotomy risks. * Has donated a unit of blood within the last 2 months at the date of informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Biospecimen & Clinical Data Collection | 10 years | To collect enough biospecimens and associated clinical data to allow researchers to come to statistically relevant scientific results |
Countries
United States
Contacts
Primary ContactCarolyn Bidwell
Outcome results
None listed